X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics

On September 22, 2026 X-Chem, a global leader in innovative drug discovery services, reported the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical trial of a drug candidate developed from a compound identified through an X-Chem DNA-encoded chemical library (DEL) screen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Relay Therapeutics, a leader in cutting-edge approaches to drug discovery, licensed an inhibitor of the oncology target phosphoinositide 3- kinase alpha (Pl3Ka) that was discovered through an X-Chem DEL screen. The inhibitor demonstrated differentiated pharmacology, mutant selectivity, a novel allosteric binding site and served as a starting point for Relay’s innovative development of zovegalisib (RLY-2608), currently in a clinical trial. The initiation of this Phase 3 trial represents a milestone under the companies’ Research Collaboration and License Agreement.

"The unique selectivity and binding site of RLY-2608 are a testament to the power of the X-Chem DEL platform to discover unique chemical matter with differentiated pharmacology," said X-Chem CEO Karen Lackey. "We are thrilled that our discovery platforms helped provide a starting point for a potential new treatment for patients with breast cancer. Hats off to the Relay team for having the drive and vision to push this project forward."

"X-Chem’s excellence in DEL technology was apparent from the very beginning of this exciting project, and we are pleased to continue to advance the clinical development of zovegalisib in patients with PI3Ka-driven diseases," said Relay CEO Sanjiv Patel.

(Press release, X-Chem, SEP 22, 2026, View Source [SID1234671013])